Previous studies [26], [27] have looked at the costs of using NT-proBNP as a means to rule out HF and to reduce the levels of echocardiography referrals but these cannot address the question of an optimal cost-effective diagnostic strategy and also did not place a cost on a missed HF diagnosis. This evidence concerns the gene NPPB and hydrops fetalis.